X4 Pharmaceuticals, Inc (XFOR): restructuring charge — X4 Pharmaceuticals cuts 30% of workforce, closes Vienna facility, expects $30-35M annual savings

X4 Pharmaceuticals, Inc

Headcount reduced by 43 (~30%); Vienna facility closed; preclinical programs paused.
Estimated $3.0M in severance charges, primarily in Q1 2025.
Annual spending expected to decrease by $30-35M; cash runway into first half 2026.
Phase 3 trial for mavorixafor in chronic neutropenia enrollment on track for mid-2025.
Focus on advancing mavorixafor for chronic neutropenia and optimizing XOLREMDI promotion for WHIM.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

X4 Pharmaceuticals, Inc announced a restructuring with charges of approximately $3.0 million for severance and other employee termination-related costs affecting the Company (43 employees, or approximately 30% of the Company’s employees).

Type: restructuring
Charge: approximately $3.0 million for severance and other employee termination-related costs
Affected area: the Company
Headcount: 43 employees, or approximately 30% of the Company’s employees

Exact text from the filing

The Company estimates that it will incur charges of approximately $3.0 million for severance and other employee termination-related costs, primarily in the first quarter of 2025.

View on SEC.gov

7 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

X4 Pharmaceuticals, Inc filing history →

Source: SEC EDGAR

accession 0001628280-25-004254

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.